A phase II multicenter study of combined @entity1945 and XXXX as first line chemotherapy for @entity1149 .

@entity1 @entity137 @entity417 @entity882 @entity902 @entity221 @entity957 @entity1149 @entity1395 @entity344 @entity420 @entity1398 @entity204 @entity136 @entity1945
This trial was designed to determine the 1-year survival rate, efficacy, and safety, produced by @entity1945 and @entity136 as first line chemotherapy in @entity1149 ( @entity1149 ). Fifty-three @entity1 were enrolled; 51 received treatment. @entity1945 1 mg/m(2), days 1-5 and @entity136 1 g/m(2) days 1 and 15 were administered IV, each drug over 30 min; cycles consisted of 28 days. Treatment continued until progressive disease or intolerable @entity137 . Nineteen @entity1 (36%) had Eastern Cooperative Oncology Group criteria performance status (ECOG PS) = 0, 34 (64%) PS = 1. Median age was 64 years; 37 @entity1 (70%) were male. HISTOLOGY: @entity420 (42%), @entity957 (28%), large cell (19%), and unclassified (11%). Among 47 evaluable @entity1 , eight (17%) had partial response, 11 (23%) had stable disease. One-year survival was 39% and median survival was 7.6 months (range, < 1-19.6). Grade 3 and 4 @entity137 included @entity1398 (53%), @entity417 (18%), @entity882 (12%), @entity1395 (8%), and @entity344 (8%); three @entity1 (6%) experienced @entity221 . There were no treatment-related @entity204 . The combination @entity1945 / @entity136 produced a 1-year survival similar to previous @entity902 -based regimens, when used as first line chemotherapy for @entity1149 . The @entity137 profile was acceptable.
